[
    [
        {
            "time": "",
            "original_text": "研发日报丨百奥泰阿达木单抗获批治疗非感染性葡萄膜炎",
            "features": {
                "keywords": [
                    "百奥泰",
                    "阿达木单抗",
                    "非感染性葡萄膜炎",
                    "获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "研发日报丨百奥泰阿达木单抗获批治疗非感染性葡萄膜炎",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "研发日报丨贝达药业ALK抑制剂NSCLC三期临床达主要终点",
            "features": {
                "keywords": [
                    "贝达药业",
                    "ALK抑制剂",
                    "NSCLC",
                    "三期临床",
                    "主要终点"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "肿瘤治疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "研发日报丨贝达药业ALK抑制剂NSCLC三期临床达主要终点",
                "Correlation": 9,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：中报窗口期继续看好业绩高增长板块 持续推荐有实力能兑现的疫苗公司",
            "features": {
                "keywords": [
                    "医药生物",
                    "中报",
                    "高增长",
                    "疫苗公司"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：中报窗口期继续看好业绩高增长板块 持续推荐有实力能兑现的疫苗公司",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "优于Xalkori！贝达药业ALK抑制剂NSCLC三期临床达主要终点",
            "features": {
                "keywords": [
                    "贝达药业",
                    "ALK抑制剂",
                    "NSCLC",
                    "Xalkori",
                    "三期临床"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "肿瘤治疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "优于Xalkori！贝达药业ALK抑制剂NSCLC三期临床达主要终点",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "时代医药周报 | 武汉出台重点监控目录，辅助用药限量降价大势所趋",
            "features": {
                "keywords": [
                    "武汉",
                    "重点监控",
                    "辅助用药",
                    "限量降价"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "政策影响"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "时代医药周报 | 武汉出台重点监控目录，辅助用药限量降价大势所趋",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "A股异动丨贝达药业(300558.SZ)涨4.44%盐酸恩沙替尼eXalt3研究中期分析结果发布",
            "features": {
                "keywords": [
                    "贝达药业",
                    "盐酸恩沙替尼",
                    "eXalt3",
                    "研究中期分析"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "肿瘤治疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股异动丨贝达药业(300558.SZ)涨4.44%盐酸恩沙替尼eXalt3研究中期分析结果发布",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558)：恩沙一线数据靓丽 创新国际化展露头角",
            "features": {
                "keywords": [
                    "贝达药业",
                    "恩沙",
                    "一线数据",
                    "创新国际化"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "国际化发展"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558)：恩沙一线数据靓丽 创新国际化展露头角",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]